Zhejiang CONBA Pharmaceutical Co.,Ltd. (SHA:600572)

SHA:600572 Ratios and Metrics

Market cap in millions CNY. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Aug 28, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Capitalization	11,147	11,680	12,979	12,156	12,850	12,105
Market Cap Growth	-9.07%	-10.01%	6.77%	-5.40%	6.16%	-23.41%
Enterprise Value	10,753	11,402	12,136	11,898	13,766	13,693
Last Close Price	4.53	4.50	4.69	4.30	4.39	4.13
PE Ratio	19.64	18.77	21.94	33.95	6.37	26.70
Forward PE	-	15.92	15.92	15.92	15.92	15.92
PS Ratio	1.75	1.79	1.93	2.03	1.96	2.05
PB Ratio	1.57	1.69	1.77	1.66	1.68	2.26
P/TBV Ratio	1.72	1.86	2.00	1.92	1.93	2.71
P/FCF Ratio	14.87	16.18	18.82	14.07	41.48	15.34
P/OCF Ratio	11.13	11.54	14.44	10.52	14.42	9.69
PEG Ratio	-	11.48	11.48	11.48	11.48	11.48
EV/Sales Ratio	1.69	1.75	1.80	1.98	2.10	2.32
EV/EBITDA Ratio	12.62	12.48	10.75	12.35	14.39	16.15
EV/EBIT Ratio	21.01	19.66	15.09	17.23	20.42	23.55
EV/FCF Ratio	14.34	15.80	17.60	13.78	44.43	17.35
Debt / Equity Ratio	0.04	0.06	0.17	0.16	0.20	0.42
Debt / EBITDA Ratio	0.33	0.46	1.10	1.24	1.55	2.66
Debt / FCF Ratio	0.37	0.59	1.80	1.39	4.82	2.85
Asset Turnover	0.60	0.62	0.61	0.54	0.64	0.62
Inventory Turnover	2.49	2.39	2.30	2.27	2.62	1.87
Quick Ratio	1.14	1.22	1.38	1.49	1.37	0.95
Current Ratio	1.90	1.76	1.82	1.93	1.73	1.27
Return on Equity (ROE)	8.52%	9.23%	9.20%	6.15%	32.90%	10.67%
Return on Assets (ROA)	3.01%	3.43%	4.54%	3.89%	4.10%	3.80%
Return on Capital (ROIC)	4.02%	4.55%	5.88%	4.89%	5.04%	4.62%
Return on Capital Employed (ROCE)	6.70%	7.90%	10.00%	8.50%	8.30%	9.70%
Earnings Yield	5.34%	5.33%	4.56%	2.95%	15.70%	3.74%
FCF Yield	6.73%	6.18%	5.31%	7.11%	2.41%	6.52%
Dividend Yield	3.33%	3.33%	4.26%	3.49%	3.65%	-
Payout Ratio	86.93%	84.11%	71.02%	136.92%	4.21%	31.50%
Buyback Yield / Dilution	-2.06%	1.59%	-0.55%	1.10%	-2.71%	5.28%
Total Shareholder Return	1.24%	4.92%	3.71%	4.59%	0.94%	5.28%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.